在极早出生的新生儿中预防性低剂量皮醇:当前的知识和未来的挑战
Olivier Baud1,2,3, Héloïse Torchin4,5, Marine Butin6,7
1Obstetrical Perinatal and Pediatric Epidemiology Research Team, EPOPE, French Institute for Medical Research and Health, Université Paris Cite, CRESS, INSERM, INRAE, Paris, France. olivbaud@gmail.com.
Pediatric research
|November 26, 2024
概括
在极低妊娠年龄的新生儿 (ELGANs) 中,预防性皮改善了没有支气管肺功能失调 (BPD) 的生存率. 虽然通常是安全的,但最佳的治疗策略需要进一步研究.
科学领域:
- 新生儿医学 新生儿医学
- 儿科药理学 儿科药理学
- 关键的护理关键的护理
背景情况:
- 极低妊娠年龄的新生儿 (ELGANs) 具有不成熟的上腺,损害了他们对产后压力的反应.
- 这种不成熟会导致严重的并发症,如死亡和支气管肺功能障碍 (BPD).
研究的目的:
- 审查ELGANs中预防性低剂量皮的证据.
- 评估其在临床实践中的好处,风险和持续挑战.
主要方法:
- 临床试验的系统审查和对最近的真实世界数据的分析.
- 讨论实施挑战和未来的研究方向.
主要成果:
- 预防性皮可以降低出院前的死亡率,并改善没有BPD的生存率.
- 益处包括专利通道动脉关闭 (PDA) 和改善心血管稳定性.
- 潜在的风险包括在特定子组中增加自发性肠孔和晚发性败血症.
结论:
- 预防性皮对ELGAN有益,改善了生存结果.
- 现实世界的数据支持试验结果,显示了没有增加不良事件的额外好处.
- 需要进一步研究最佳的患者选择,时间和治疗持续时间.
相关概念视频
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
218
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
218
COPD: Management Using Bronchodilators and Corticosteroids
179
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
179
Asthma: Pathogenesis and Management
351
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
351
Teratogenicity
2.4K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.4K
Factors Affecting Drug Response: Overview
1.9K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
1.9K
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K


